LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...

GLP-1 weight-loss drugs have already taken the Europe storm, altering consumer eating habits. Even the eating habits of GLP-1 ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

The analysis also found no statistically significant difference in the risk of NAION—non-arteritic anterior ischaemic optic ...

(HealthDay News) — For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with nonarteritic anterior ischemic optic neuropathy (NAION), according ...

In this cohort study of individuals with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use was ...

Drivers of revenue growth included more customers using multiple chronic condition programs as well as strong adoption of GLP ...

Monday, after the company known as WeightWatchers reported better-than-expected second-quarter revenue amid robust demand for GLP-1 obesity treatments. WW, which emerged from bankruptcy on June 24, ...

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36 mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

FoodBev caught up with Rafael Acevedo, Danone’s president of yogurt, to find out more about the rising trends behind the brand's new 'first-of-its-kind' innovation.

The product is viewed by the CPG giant as a “one-of-a-kind opportunity” to help consumers rebuild or maintain muscle they ...

Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 medications.